Hepatic steatosis in people older and younger than fifty who are living with HIV and HIV‐negative controls: A cross‐sectional study nested within the POPPY cohort
暂无分享,去创建一个
R. Gilson | A. Arenas-Pinto | N. Doyle | Nicholas Bakewell | Frank A Post | Ana Milinkovic | Ian Williams | Jaime Vera | Jane Anderson | Michelle Beynon | Alastair O'Brien | Sarah L Pett | Alan Winston | Caroline A Sabin | F. Post | Jaime H. Vera | Ian Williams
[1] Yang Zou,et al. Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population , 2022, BMC Gastroenterology.
[2] Myeong Jun Song,et al. Advancing the global public health agenda for NAFLD: a consensus statement , 2021, Nature Reviews Gastroenterology & Hepatology.
[3] J. Rockstroh,et al. Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART) , 2021, EClinicalMedicine.
[4] J. Esplugues,et al. NNRTI and Liver Damage: Evidence of Their Association and the Mechanisms Involved , 2021, Cells.
[5] F. Bendtsen,et al. Hepatic steatosis associated with exposure to elvitegravir and raltegravir. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[6] C. Sirlin,et al. Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] M. Zins,et al. Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in General Population: the French Nationwide NASH-CO Study. , 2020, Gastroenterology.
[8] A. Winston,et al. Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross‐sectional analysis , 2020, HIV medicine.
[9] J. Milic,et al. Prevalence, predictors and severity of lean non-alcoholic fatty liver disease in HIV-infected patients. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[10] P. Bossuyt,et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. , 2020, Journal of hepatology.
[11] G. Sebastiani,et al. Nonalcoholic Fatty Liver Disease and the Development of Metabolic Comorbid Conditions in Patients With Human Immunodeficiency Virus Infection , 2020, The Journal of Infectious Diseases.
[12] Richard D Moore,et al. Weight gain among treatment‐naïve persons with HIV starting integrase inhibitors compared to non‐nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada , 2020, Journal of the International AIDS Society.
[13] F. Palella,et al. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] R. Loomba,et al. Advances in non-invasive assessment of hepatic fibrosis , 2020, Gut.
[15] H. Stellbrink,et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] C. Fìlice,et al. Drug-induced liver steatosis in patients with HIV infection. , 2019, Pharmacological research.
[17] K. Sherman,et al. Fatty liver disease in persons with HIV infection. , 2019, Topics in antiviral medicine.
[18] A. Winston,et al. Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study. , 2018, International journal of epidemiology.
[19] R. Hultcrantz,et al. Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long‐term follow‐up study , 2017, Hepatology communications.
[20] Michael T. Lu,et al. Differential relationships of hepatic and epicardial fat to body composition in HIV , 2017, Physiological reports.
[21] E. Verna,et al. Managing nonalcoholic fatty liver disease in patients living with HIV , 2016, Current opinion in infectious diseases.
[22] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[23] M. Budoff,et al. Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study , 2014, The American Journal of Gastroenterology.
[24] Korbinian Brand,et al. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. , 2013, Journal of hepatology.
[25] C. Thio,et al. HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. , 2012, The Journal of infectious diseases.
[26] C. Torti,et al. Evaluation of liver fibrosis: concordance analysis between noninvasive scores (APRI and FIB-4) evolution and predictors in a cohort of HIV-infected patients without hepatitis C and B infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] H. Kim,et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[28] N. Lundbom,et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. , 2009, Gastroenterology.
[29] G. Ligabue,et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[30] Eric Schulte Nordholt. Imputation: Methods, Simulation Experiments and Practical Examples , 1998 .
[31] B. Fromenty,et al. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. , 2011, Journal of hepatology.